Description
The domain expert identified high safety risks from mitochondrial overactivation but the debate didn’t establish safe dosing parameters. This knowledge gap is critical for clinical translation of PINK1/Parkin-targeted therapies.
Source: Debate session sess_SDA-2026-04-10-SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 (Analysis: SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9)
Resolution criteria
Resolution requires: (1) dose-response study of PINK1/Parkin agonists (e.g., CCCP, valinomycin analogues) or mitophagy inducers in wild-type vs mitochondrial toxicity reporter mice, measuring therapeutic window (ED50 vs LD50) where mitophagy is enhanced >=50% without mitochondrial dysfunction markers (caspase activation, cytochrome c release) exceeding baseline; (2) patient-derived iPSC neurons with PINK1/Parkin mutations testing mitophagy enhancement at doses validated safe in mouse, measuring therapeutic index >=5; (3) longitudinal human data (PD patients on mitophagy enhancers) establishing safety margins and efficacy signals. Preclinical safety data without human translation data is insufficient for clinical development.